about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

Re­gen­eron posts sec­ond look on Covid-19 an­ti­body cock­tail, boost­ing its case for EUA — but what about symp­tom ...

5 years ago
R&D
Coronavirus

News brief­ing: Spring­Works, Jazz ex­change $35M and PTSD drug; Dr. Red­dy's says cy­ber­at­tack was ran­somware

5 years ago
News Briefing

Re­meGen read­ies $514M IPO as HKEX adds jew­el to the crown

5 years ago
Financing

Chi­nese rare dis­ease play­er inks first deal around nar­colep­sy drug Wak­ix af­ter grab­bing $80M to build an ecosys­tem

5 years ago
Deals
China

Once re­ject­ed, Kala's dry eye drug now gains en­try to a field where No­var­tis is groom­ing its own block­buster

5 years ago
Pharma
FDA+

The dis­rup­tors at EQRx have their eyes on the PD-(L)1 mar­ket — tee­ing up $150M cash to grab 2 back­bone ther­a­pies ...

5 years ago
Deals
China

News brief­ing: As­traZeneca fol­lows Am­gen down KRAS/SHP2 com­bo path; Val­lon Phar­ma­ceu­ti­cals files for $17 mil­lion ...

5 years ago
News Briefing

Pan­dem­ic trav­el re­stric­tions force FDA to de­lay a BLA re­view — in­volv­ing a site in­spec­tion in Ko­rea

5 years ago
FDA+

Fi­bro­Gen’s new PhI­II da­ta set it up for quick OK, an­a­lysts say. But can it avoid a black box warn­ing?

5 years ago
R&D

Ul­tragenyx in­jects $40M to grab Solid's mi­crody­s­trophin trans­gene — while side­step­ping the AAV9 vec­tor that stirred ...

5 years ago
Deals
Cell/Gene Tx

Chi­nese in­vestors wa­ger $105M on an IPO-bound biotech look­ing to push RNAi as main­stream can­cer ther­a­py

5 years ago
Financing
China

Can B cells break the bound­aries of cell ther­a­py? Long­wood start­up has $52M to prove a new en­gi­neer­ing tech

5 years ago
Financing
Startups

Roche wades deep­er in­to Covid-19 fight, ink­ing an­tivi­ral pact with $350M cash fol­low­ing Re­gen­eron deal

5 years ago
Deals
Coronavirus

Glax­o­SmithK­line's vac­cines group aims for a first as it kicks off PhI­II RSV stud­ies

5 years ago
R&D

Un­fazed by PhII miss, Roche ush­ers Prothena's Parkin­son's drug in­to late-stage tri­al — a $60M move

5 years ago
R&D

Spar­ingVi­sion rais­es $52M to kick off long jour­ney for a next-gen gene ther­a­py that goes much, much broad­er than ...

5 years ago
Financing
Cell/Gene Tx

Roche finds a home for a new, $500M man­u­fac­tur­ing lo­gis­tics hub, promis­ing 500 jobs

5 years ago
People
Outsourcing

Covid-19 roundup: Stéphane Ban­cel sees De­cem­ber EUA for Mod­er­na at ear­li­est; Trump trash­es Fau­ci as 'dis­as­ter' and ...

5 years ago
Coronavirus

News brief­ing: Ab­b­Vie and Roche's Ven­clex­ta scores an­oth­er FDA OK; Im­muno­Gen nabs Chi­na deal with $40M cash

5 years ago
News Briefing

What about the Ger­man ne­go­ti­a­tion mod­el? Biden steers drug pric­ing de­bate to a show­down

5 years ago
Pharma

CAR-plus: Irish biotech re­cruits Kite alum Chris Now­ers to prep dual-tar­get­ing NK cell ther­a­py for the clin­ic

5 years ago
Financing
Cell/Gene Tx

UCB sketch­es grand plans for new head­quar­ters as it grabs Eli Lil­ly's aban­doned neu­ro R&D cam­pus

5 years ago
Pharma

Covid-19 roundup: Can Ab­b­Vie’s dis­ap­point­ing NASH drug ceni­crivi­roc find suc­cess fight­ing cy­tokine storms?; Trump ...

5 years ago
Coronavirus

Fore­site pulls Gem­i­ni Ther­a­peu­tics to Nas­daq in a quick $216M SPAC flip

5 years ago
Deals
First page Previous page 63646566676869 Next page Last page
A service from the Financial Times